GILD Quote, Trading Chart, Gilead Sciences Inc.
home / stock / gild / gild quote
$67.18 Last:
0.8% Change Percent:
$66.77 Open:
$67.18 Previous Close:
$68.2401 High:
$66.65 Low:
4,984,007 Volume:
06/24/2021 04:41:56 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
GILD Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-24 | 66.77 | 67.18 | 68.2401 | 66.65 | 4,984,007 |
| 2021-06-23 | 67.21 | 66.65 | 67.25 | 66.56 | 4,203,208 |
| 2021-06-22 | 67.238 | 67.05 | 67.6 | 66.775 | 4,794,822 |
| 2021-06-21 | 66.99 | 67.35 | 67.565 | 66.77 | 5,309,395 |
| 2021-06-18 | 67 | 66.61 | 67.18 | 65.89 | 11,433,081 |
| 2021-06-17 | 67.32 | 67.22 | 67.48 | 66.49 | 6,953,742 |
| 2021-06-16 | 68.2162 | 67.33 | 69.3399 | 67.19 | 12,925,653 |
| 2021-06-15 | 68.48 | 68.09 | 68.5 | 67.74 | 6,448,986 |
| 2021-06-14 | 68.01 | 68.15 | 68.325 | 67.47 | 5,306,791 |
| 2021-06-11 | 69.14 | 68.77 | 69.25 | 68.645 | 6,906,646 |
| 2021-06-10 | 68.99 | 69.29 | 69.705 | 68.47 | 8,645,128 |
| 2021-06-09 | 67.57 | 68.65 | 69.19 | 67.52 | 8,390,601 |
| 2021-06-08 | 67.44 | 67.38 | 67.61 | 66.99 | 3,602,359 |
| 2021-06-07 | 67.605 | 67.42 | 67.9644 | 67.11 | 7,833,911 |
| 2021-06-04 | 66.79 | 67.43 | 67.57 | 66.54 | 6,310,083 |
| 2021-06-03 | 65.96 | 66.48 | 66.6 | 65.7933 | 6,720,065 |
| 2021-06-02 | 65.59 | 66.03 | 66.35 | 65.54 | 6,568,847 |
| 2021-06-01 | 66.44 | 65.32 | 66.55 | 65.12 | 6,554,212 |
| 2021-05-31 | 66.05 | 66.11 | 66.685 | 65.8 | 5,940,055 |
| 2021-05-28 | 66.05 | 66.11 | 66.685 | 65.8 | 5,937,304 |
News, Short Squeeze, Breakout and More Instantly...
-
-- Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients -- -- Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts -- Kite, a Gilead Com...
-
A large part of a $5 billion bet that Gilead Sciences (NASDAQ: GILD) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (NASDAQ: GLPG) ...
-
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the ...